Drugs / ADX-038
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05876312 | Aug 2023 → Mar 2028 expected | paroxysmal nocturnal hemoglobinuria | ADARx Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07522099 | May 2026 → Jul 2028 expected | IgA glomerulonephritis, complement 3 glomerulopathy, membranoproliferative glomerulonephritis | ADARx Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT06990269 | Nov 2025 → Feb 2030 expected | age-related macular degeneration | ADARx Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT06989359 | Aug 2025 → Dec 2028 expected | IgA glomerulonephritis, complement 3 glomerulopathy, immunoglobulin-mediated membranoproliferative glomerulonephritis | ADARx Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
Press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-12-02 | ADARx Pharmaceuticals, Inc. | Phase 2 Study of ADX-038 in Participants With Geographic Atrophy adarx.com ↗ |
| 2024-12-02 | ADARx Pharmaceuticals, Inc. | Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease adarx.com ↗ |
| 2024-11-03 | ADARx Pharmaceuticals, Inc. | Safety, Tolerability, PK and PD of ADX-038 in HV and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients adarx.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ADX-038 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06990269 ↗ |
| Modality | Small interfering RNA (siRNA) | “siRNA duplex oligonucleotide” NCT05876312 ↗ |
| Route | Subcutaneous | “Subcutaneously Administered ADX-038” NCT06990269 ↗ |